Novartis reported 201M in Interest Expense on Debt for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Alcon AG ALC:SW 30M 1000K
Amgen AMGN:US $ 281M 4M
Biogen BIIB:US $ 56.4M 8.3M
Bristol Myers Squibb BMY:US $ 330M 23M
Eli Lilly And LLY:US $ 86.9M 0.9M
Fresenius Medical Care FME:GR € 83M 8M
Genmab GEN:DC 3M 0
Gilead Sciences GILD:US $ 256M 1M
Lonza Group LONN:SW 29M 7M
Novartis NOVN:VX 201M 1000K
Novartis NVS:US $ 201M 1M
Pfizer PFE:US $ 316M 20M
Recordati REC:IM 4.58M 380K
Regeneron Pharmaceuticals REGN:US $ 14.4M 0.2M